Optimisation of Mechanical Insufflation:Exsufflation
MIE2
Investigating Methods to Improve Secretion Clearance Using Mechanical Insufflation:Exsufflation in Patients With Neuromuscular Disease.
1 other identifier
interventional
30
1 country
1
Brief Summary
Patients with neuromuscular diseases (NMD) can suffer from a range of respiratory problems due to respiratory muscle weakness. Cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. Therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (MIE). Although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. Increasingly, higher pressures are used during MIE and recent work has demonstrated that there may be a physiological benefit to this. However, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as NMD patients frequently have concurrent heart muscle weakness. Further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance. The overall aim of this study is to investigate methods to manipulate MIE to improve secretion clearance in patients with NMD. The questions it seeks to answer are: (i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to MIE also cause throat closure (iv) what factors do patients believe contribute to their adherence to MIE therapy? Patients with slowly progressive or stable neuromuscular diseases will be included in the study. Participation will involve two visits to the Lane Fox Respiratory Unit, each lasting approximately four hours. Patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Dec 2019
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 12, 2019
CompletedFirst Posted
Study publicly available on registry
November 14, 2019
CompletedStudy Start
First participant enrolled
December 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
May 31, 2025
CompletedApril 3, 2024
March 1, 2024
5.3 years
November 12, 2019
April 2, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Cough peak expiratory flow (cPEF)
Change in cPEF with different modalities of MI-E
2 days
Study Arms (2)
Insufflation optimisation
EXPERIMENTALPatient will receive different inspiratory time and expiratory time, and inspiratory flow at a fixed insufflation pressure. To determine how best to recruit lung.
Exsufflation optimisation
EXPERIMENTALPatient will receive different expiratory pressures at a fixed inspiratory pressure (optimal determine in Arm 1). To determine minimum flow bias needed to generate cPEF
Interventions
Patients will receive different inspiratory (Ti) and expiratory (Te) times and inspiratory flows, at a fixed insufflation and exsufflation pressure. Optimum insufflation pressure will be determined by measuring maximal inspiratory capacity.
Patients will receive different exsufflation pressures at fixed insufflation pressure.
Eligibility Criteria
You may qualify if:
- Stable or slowly progressive neuromuscular disease
- Respiratory muscle weakness (FVC \<60%, snip \<60%, sleep disordered breathing)
- Clinical evidence of respiratory secretions or cough peak expiratory flow \<270 and history of lower respiratory tract infection
- Documented clinical stability by supervising clinician
You may not qualify if:
- Rapidly progressive neuromuscular disease (such as motor neuron disease)
- Decompensated respiratory failure (pH \< 7.35)
- Pregnancy
- Aged \<18
- Change in ventilator settings in preceding 4 weeks
- Significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Guys & St. Thomas' NHS Foundation Trust
London, SE1 7EH, United Kingdom
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Patrick Murphy, PhD
Guy's and St Thomas' NHS Foundation Trust
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- SEQUENTIAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 12, 2019
First Posted
November 14, 2019
Study Start
December 19, 2019
Primary Completion
March 31, 2025
Study Completion
May 31, 2025
Last Updated
April 3, 2024
Record last verified: 2024-03
Data Sharing
- IPD Sharing
- Will not share